At this year’s ASCO Virtual Annual Meeting, Biognosys is proud to present two abstracts, highlighting our work with IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy, and Indivumed, we demonstrate the utility of our next-generation proteomics platform to advance the understanding of cancer biology and identify novel biomarkers and therapeutic targets in oncology clinical research:
Session:
Publication Only: Melanoma/Skin Cancers
Authors:
Kamil Sklodowski, Domenico Mallardo, Jakob Vowinckel, Mariaelena Capone, Martin Soste, Gabriele Madonna, Vito Vanella, Sarah Warren, Paolo Antonio Ascierto;
Biognosys AG, Schlieren, Switzerland; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori–Fondazione “G. Pascale”, Naples, Italy; Biognosys, Schlieren, Switzerland; Istituto Nazionale Tumori Pascale, Naples, Italy; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS Fondazione “G. Pascale”, Naples, Italy; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy; NanoString Technologies, Inc., Seattle, WA
Session:
Publication Only: Gastrointestinal Cancer – Colorectal and Anal
Authors:
Jakob Vowinckel, Thomas Corwin, Jonathan Woodsmith, Tobias Treiber, Roland Bruderer, Lukas Reiter, Eike-Christin von Leitner, Karel Novy, Hartmut Juhl, Oliver Rinner, Indivumed Authors;
Biognosys, Schlieren, Switzerland; INDIVUMED GMBH, Hamburg, Germany; Biognosys, Zurich, Switzerland; Indivumed GmbH, Hamburg, Germany
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
